2013-03-04 10:35:16 -

Biotie Therapies Corp.          Stock Exchange Release    4 March 2013 at 11.30
a.m.

Change in the number of votes relating to Biotie Therapies Corp.'s shares

The Swiss subsidiary of Biotie Therapies Corp. ("Biotie" or the
"Company"),
Biotie Therapies AG (previously Synosia Therapeutics Holding AG and Biotie
Therapies Holding AG) has conveyed Biotie shares against consideration pursuant
to the option programs as follows:

               February 2013 Total (5/2011-     Options % of the total  
                                    2/2013) outstanding      amount of
                                                                shares

                    30,680        6,594,588   7,962,603           1.8%




The conveyance of Biotie shares relates to the option plan of Synosia
Therapeutics Holding AG (currently Biotie Therapies Holding AG, "Synosia")
acquired by Biotie in February 2011. According to such Synosia share option
plan, options have been granted to employees, former directors and consultants.
In connection with the completion of the acquisition of Synosia, the option plan
was amended so that instead of shares in Synosia an aggregate maximum of
14,912,155 shares in Biotie may be subscribed based on the plan. Biotie issued
these 14,912,155 shares to its current subsidiary Synosia in connection with the
acquisition to be further conveyed to the option holders when they potentially
exercise their option rights in accordance with the terms and conditions of the
option program.

The conveyed shares previously held by the Company's subsidiary have not carried
any voting rights. The parent company Biotie does not own any treasury shares.
The conveyance does not affect the number of registered shares.

After the conveyances the changes are as follows:

 The increase of vote  A total amount of      The number of the The total number
       of the Company     voting rights:   Company's share held    of registered
        February 2013                              by the Group           shares
                                                  February 2013

               30,680        444,393,171                             452,710,738
                                                      8,317,567




Turku, 4 March 2013

Biotie Therapies Corp.

Timo Veromaa
President and CEO

For further information, please contact:

Virve Nurmi, Biotie Therapies Corp.
tel. +358 2 274 8900
e-mail: virve.nurmi@biotie.com

DISTRIBUTION
NASDAQ OMX Helsinki Ltd
Main Media
www.biotie.com




This announcement is distributed by Thomson Reuters on behalf of 
Thomson Reuters clients. The owner of this announcement warrants that: 
(i) the releases contained herein are protected by copyright and 
    other applicable laws; and 
(ii) they are solely responsible for the content, accuracy and 
     originality of the information contained therein. 
    
Source: Biotie Therapies Oyj via Thomson Reuters ONE
[HUG#1682664]